Home » Stocks » SAGE

Sage Therapeutics, Inc. (SAGE)

Stock Price: $74.89 USD -0.18 (-0.24%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $72.85 -2.04 (-2.72%) May 11, 8:42 AM
Market Cap 4.38B
Revenue (ttm) 1.11B
Net Income (ttm) 637.05M
Shares Out 58.37M
EPS (ttm) 11.66
PE Ratio 6.42
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $74.89
Previous Close $75.07
Change ($) -0.18
Change (%) -0.24%
Day's Open 74.10
Day's Range 72.64 - 75.99
Day's Volume 282,880
52-Week Range 33.82 - 98.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 17.17% and -18.78%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people ...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

1 week ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

3 weeks ago - Business Wire

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule...

Other stocks mentioned: BIIB
4 weeks ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatmen...

Other stocks mentioned: BIIB
4 weeks ago - Business Wire

Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.

Other stocks mentioned: BIIB, GILD, VRTX
1 month ago - Investors Business Daily

Investors need to pay close attention to Sage Therapeutics (SAGE) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

When stocks are punished, it's not always for a good reason.

Other stocks mentioned: BIIB, CCL, CCR, LL, SKY, VIAC
1 month ago - GuruFocus

Though these stocks have dropped, upcoming news offers hope for them to rebound.

Other stocks mentioned: BLUE, TRIL
1 month ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with de...

1 month ago - Business Wire

Other stocks mentioned: BIO, INVA
1 month ago - GuruFocus

Can this brain health-focused biotech continue to rise, or will it fade -- again?

1 month ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) today reported complete 12-month data from the 30 mg cohort and interim data from the 50 mg cohort of the ongoing Phase 3 open-l...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilita...

1 month ago - Business Wire

A Relative Strength Rating upgrade for Sage Therapeutics shows improving technical performance. The post Sage Therapeutics Shows Rising Price Performance With Jump To 81 RS Rating appeared first on Inve...

2 months ago - Investors Business Daily

With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.

Other stocks mentioned: EXPE, MAT, T, URBN, CME, CP, GBT ...
2 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...

2 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

3 months ago - Business Wire

American BriVision: Deep Dive Into Market Potential

Other stocks mentioned: ABVC, BIIB, KMDA, MRK, SGEN
3 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

4 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of peop...

4 months ago - Business Wire

Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.

Other stocks mentioned: BLUE, GLPG
4 months ago - The Motley Fool

Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.

Other stocks mentioned: BIIB
5 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of...

5 months ago - Business Wire

The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1.5 billion...

5 months ago - Schaeffers Research

Biogen (BIIB) and Sage Therapeutics (SAGE) collaborate to develop latter's zuranolone for depression indications and SAGE-324 for essential tremor.

Other stocks mentioned: BIIB
5 months ago - Zacks Investment Research

Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 billion in cas...

Other stocks mentioned: BIIB
5 months ago - Market Watch

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to...

Other stocks mentioned: BIIB
5 months ago - Business Wire

Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 41.67% year over year to ($2.03), which beat the estimate ...

6 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

6 months ago - Business Wire

Sage Therapeutics has shown impressive results on the charts YTD, where shareholders have enjoyed +169% gains since the selloff. The stock has bounced away from support nicely 5 times since then, with n...

6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the ...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives o...

7 months ago - Business Wire

Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

With depression rates up amid the economic and health crises, mental health should be treated like a physical illness, Sage Therapeutics CEO Jeff Jonas said on "Mad Money."

8 months ago - CNBC

Sage Therapeutics CEO: Mental health is integral to returning to work

YouTube video

"We need to treat mental health like a physical illness, treat it urgently, in order to get people back to work and back to their families," Sage Therapeutics CEO Jeff Jonas said.

8 months ago - CNBC Television

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc.

8 months ago - Business Wire

Sage Therapeutics, Inc. (SAGE) CEO Jeffrey Jonas on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Shares of Sage Therapeutics (NASDAQ:SAGE) were flat in pre-market trading after the company reported Q2 results.

9 months ago - Benzinga

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc.

9 months ago - Business Wire

About SAGE

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 18, 2014
CEO
Jeffrey Jonas
Employees
298
Stock Exchange
NASDAQ
Ticker Symbol
SAGE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 22 analysts, the average rating for SAGE stock is "Buy." The 12-month stock price forecast is 100.55, which is an increase of 34.26% from the latest price.

Price Target
$100.55
(34.26% upside)
Analyst Consensus: Buy